Graphite Bio Inc

GRPH 4 | $3.27 1.84% 490K

(0.0% 1d) (3.6% 1m) (9.1% 1y) (0.0% 2d) (-2.8% 3d) (0.0% 7d) (-33.57% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 190,434,748
https://graphitebio.com
Sec Filling | Patents | 27 employees

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

gene therapies

add to watch list Paper trade email alert is off

iCoreConnect Inc.

ICCT | $1.2 0.0% 62K

Professional, Scientific, and T...

(0.0% 1d) (-4.8% 1m) (823.1% 1y) (0.0% 2d) (-4.8% 3d) (-9.1% 7d) (-63.12% volume)
Earnings Calendar:
Market Cap: $ 10,741,766

Sec Filling | Patents | 25 employees

icoreconnect creates software that allows anyone to share information at the highest security levels in the country, backed by highly-engaged customer support. the company provides secure communications for high-compliance industries including healthcare, finance and legal. icoreconnect’s software allows organizations and individuals to freely and easily exchange information with 2048-bit encryption, and in full compliance of current federal laws.

communication

add to watch list Paper trade email alert is off

Nukkleus Inc.

NUKK | $0.8758 -6.24% 140K

Professional, Scientific, and T...

(0.0% 1d) (6.7% 1m) (439900.0% 1y) (0.0% 2d) (5.4% 3d) (3.5% 7d) (-11.26% volume)
Earnings Calendar:
Market Cap: $ 0
https://www.nukk.com/
Sec Filling | Patents | 1 employees

(US) nukkleus, inc. (otc: nukk) is a fintech group that acquires, builds and scales blockchain and digital financial services businesses. the portfolio serves b2b and institutional clients with the aim of disrupting the banking & investment industry for the better.

add to watch list Paper trade email alert is off

Pyxis Oncology Inc

PYXS | $4.51 -6.63% -7.1% 470K

Professional, Scientific, and T...

(0.0% 1d) (-6.2% 1m) (50.5% 1y) (0.0% 2d) (3.0% 3d) (-1.8% 7d) (117.08% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 262,181,521
https://pyxisoncology.com
Sec Filling | Patents | 2021 employees

Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.

cancer t-cell

add to watch list Paper trade email alert is off

VERDE BIO HOLDINGS, INC.

VBHI | $0.0003 60.0% 1.3M

Professional, Scientific, and T...

(0.0% 1d) (-25.0% 1m) (-57.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-46.42% volume)
Earnings Calendar:
Market Cap: $ 623,580
https://www.verdebh.com/
Sec Filling | Patents | 1 employees

(US)

add to watch list Paper trade email alert is off

Cyclo Therapeutics Inc - Class A

CYTH | $1.22 0.83% 0.82% 30K

Professional, Scientific, and T...

(0.0% 1d) (-21.8% 1m) (74.0% 1y) (0.0% 2d) (0.0% 3d) (-3.2% 7d) (211.47% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 35,033,203
https://www.cyclotherapeutics.com
Sec Filling | Patents | 8 employees

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

cholesterol genetic alzheimer alzheimer’s

add to watch list Paper trade email alert is off